What Is “Homologous Use” — and Why Does It Matter for Umbilical Cord Blood?
⚠ Medical & Regulatory Disclaimer: The information in this article is intended for educational purposes only and does not constitute medical advice, legal counsel, or regulatory guidance. Umbilical cord blood products are regulated by the U.S. Food and Drug Administration (FDA). The clinical applications discussed below represent areas of active research and established medical use; they do not imply that any specific product is approved, cleared, or authorized for any particular indication. Patients and healthcare providers should consult qualified medical professionals before making any treatment decisions. Manufacturers and distributors of HCT/P products should consult regulatory counsel to confirm compliance with 21 CFR Part 1271 and applicable FDA guidance.
If you’ve been following developments in regenerative medicine, you’ve probably heard the term “homologous use” — but what does it actually mean, and why does it determine so much about how umbilical cord blood products can be used?
The short answer: under FDA regulations, a minimally manipulated cord blood product can be used without requiring full drug approval only when it’s put to a homologous use — meaning it performs the same basic function in the recipient as it does in the donor. Understanding this principle opens a surprisingly broad range of legitimate, evidence-supported clinical applications.
The Regulatory Foundation
Under 21 CFR Part 1271 and Section 361 of the Public Health Service Act, human cell and tissue products (HCT/Ps) that are minimally manipulated and used homologously can be regulated without a Biologics License Application (BLA) or Investigational New Drug (IND) application. The FDA defines homologous use as:
“The repair, reconstruction, replacement, or supplementation of a recipient’s cells or tissues with an HCT/P that performs the same basic function or functions in the recipient as in the donor.”
— 21 CFR §§1271.3(c)
For umbilical cord blood specifically, the FDA has identified its core function as forming and replenishing the lymphohematopoietic system — that is, producing and maintaining blood and immune cells. Any clinical application that replicates this function in a recipient is, by definition, homologous. But cord blood does more than make blood cells. It also carries platelets rich in growth factors, immune effectors, and progenitor cells that respond to injury. Each of these functions provides a potential homologous use anchor.
1. Hematopoietic Reconstitution: The Gold Standard
This is the most established — and FDA-recognized — homologous use of cord blood, and it has been standard of care for decades.
When a patient’s bone marrow is damaged, destroyed, or dysfunctional, cord blood transplantation can restore the body’s blood-forming capacity. The hematopoietic stem and progenitor cells (HSPCs) in cord blood engraft in the recipient’s marrow and rebuild the entire blood cell lineage — exactly the function they serve in the fetal donor.
Indications with strong clinical evidence include:
- Aplastic anemia and inherited bone marrow failure syndromes (Fanconi anemia, Diamond-Blackfan anemia)
- Myelodysplastic syndromes (MDS)
- Acute and chronic leukemias requiring myeloablative conditioning
- Sickle cell disease and beta-thalassemia
- Post-chemotherapy or radiation bone marrow ablation
More than 40,000 cord blood transplants have been performed worldwide since the first procedure in 1988 (Ruggeri et al., Stem Cells Translational Medicine, 2023). Outcomes data from major registries including the National Cord Blood Program (NCBP) and the Cord Blood Transplantation Study (COBLT) confirm durable engraftment across a wide range of patients and HLA-mismatch levels.
2. Primary and Secondary Immunodeficiencies
Because cord blood’s lymphohematopoietic function encompasses immune reconstitution as well as hematopoietic reconstitution, using it to restore immune function in patients with immunodeficiency is a directly homologous application.
Cord blood is particularly well-suited for this purpose. Its cells are immunologically naive — predominantly naïve CD45RA+ T cells, with a high proportion of regulatory T cells (Tregs) — which means it can reconstitute immune function with a reduced risk of graft-versus-host disease (GvHD), even across partial HLA mismatches.
Published clinical data confirms:
- Over 100 cord blood transplants for primary immunodeficiencies (including SCID and Wiskott-Aldrich syndrome) have been reported, with immune reconstitution comparable to other stem cell sources and low rates of severe GvHD (Bhattacharya et al., 2008).
- T-cell recovery progresses from initial CD45RO+ engraftment to de novo thymic production of naïve T cells within 12–24 months post-transplant — direct evidence of functional immune reconstitution.
- Applications extend to secondary immunodeficiencies, including immune suppression from HIV, chemotherapy, or chronic infection.
3. Wound Healing and Tissue Repair
Blood participates in wound healing. Always has. When tissue is injured, the body’s repair response begins with the arrival of blood-borne platelets, growth factors, and progenitor cells. Cord blood does this in the donor, and supplementing this same process in a recipient is a defensible homologous use argument.
Cord blood platelets are especially potent in this context. Cord blood platelet lysate (UCB-PL) contains significantly higher concentrations of platelet-derived growth factor (PDGF-AB) and transforming growth factor-beta (TGF-β) than adult peripheral blood platelet lysate — key drivers of tissue repair and angiogenesis (Weng et al., Research Square, 2025).
Clinical evidence includes:
- A pilot study evaluating UCB platelet gel in chronic venous ulcer patients found 80% of patients showed significantly decreased wound size after four weekly applications, with improvements in wound bed score, pain, and quality of life (Perez et al., 2022).
- A retrospective study of 64 chronic non-healing lower extremity wounds treated with cryopreserved UCB allograft showed complete healing in 51 of 64 wounds (79.7%), with a mean healing time of 5.53 weeks (Raphael, Wounds, 2016).
- A randomized study of locally delivered umbilical cord mesenchymal stromal cells in long-term non-healing wounds demonstrated pronounced granulation tissue growth, improved microcirculation, and wound size reduction versus placebo (Tarte et al., 2020).
4. Critical Limb Ischemia and Peripheral Vascular Disease
Oxygen and nutrient delivery is one of blood’s most fundamental roles. In ischemic conditions — where tissues are deprived of blood supply — cord blood’s vascular biology becomes directly relevant.
Cord blood contains endothelial progenitor cells (EPCs) that contribute to neovascularization, mirroring their role in fetal vascular development. Using cord blood to support perfusion in ischemic tissue supplements the same oxygenation and vascular maintenance function it performs in the donor.
Clinical evidence:
- A Phase I clinical trial (Jeon et al., 2013) assessed intramuscular injection of UCB-derived mesenchymal stem cells in patients with critical limb ischemia (CLI) secondary to atherosclerosis obliterans and thromboangiitis obliterans. Safety was established, with preliminary efficacy signals including improved ankle-brachial index and reduced pain.
- A separate clinical trial (NCT02287831) evaluated UCB-MSC implantation in patients with peripheral arterial disease — including thromboangiitis obliterans, atherosclerosis obliterans, and diabetic foot.
- A broader review (Henning et al., 2016) summarized positive preclinical and early-phase clinical evidence for UCB in both myocardial and cerebral ischemia, noting that the majority of preclinical studies demonstrated benefit.
5. Hemostatic Support
Hemostasis — stopping bleeding and initiating clot formation — is a core function of blood, including cord blood. Platelets and coagulation factors are native to cord blood in the donor. Supplementing these functions in a recipient with thrombocytopenia or coagulopathy directly mirrors the donor function.
Cord blood platelet lysate has been studied as a clinically relevant source of hemostatic and regenerative growth factors, with biologically active concentrations of PDGF-AB, TGF-β, VEGF, and other mediators demonstrated to remain stable for therapeutic applications (Weng et al., 2025).
For patients with thrombocytopenia — whether from chemotherapy, bone marrow failure, or other causes — cord blood’s platelet-mediated hemostatic function represents a biologically grounded homologous use argument.
Putting It Together
The table below summarizes each application and its supporting evidence tier:
| Application | Homologous Anchor | Evidence Level |
| Hematopoietic reconstitution | Core lymphohematopoietic function | Strong — decades of transplant data |
| Immunodeficiency treatment | Immune reconstitution | Strong — 100+ published cases |
| Wound healing / tissue repair | Blood-mediated hemostasis and repair | Moderate — multiple clinical studies |
| Critical limb ischemia | Vascular perfusion and oxygenation | Early clinical — Phase I established |
| Hemostatic support | Platelet-mediated hemostasis | Moderate — growth factor & platelet data |
A Word on Regulatory Boundaries
The FDA has been explicit that homologous use for cord blood means performing the same function as in the donor — and has issued warning letters to manufacturers who marketed UCB products for indications without a defensible homologous use rationale. The applications covered in this article are grounded in cord blood’s biological functions and supported by published clinical evidence, but that does not mean they are all equivalently established or that any specific product is authorized for any specific use.
Conclusion
Umbilical cord blood is one of the most clinically versatile biological materials in regenerative medicine — not because it has been repurposed beyond its biology, but precisely because its biology is so rich. From rebuilding a destroyed immune system to closing a chronic wound to restoring perfusion in an ischemic limb, the homologous use framework, properly applied, supports a meaningful spectrum of applications rooted in what cord blood naturally does.
The science is advancing rapidly. The regulatory pathway is navigable. The key is building every application on a solid foundation: what does cord blood do in the donor — and is that the same thing we’re asking it to do in the recipient?
References
1. U.S. FDA. 21 CFR Part 1271 — Human Cells, Tissues, and Cellular and Tissue-Based Products.
2. U.S. FDA. 21 CFR §1271.3(c) — Definition of Homologous Use.
3. U.S. FDA. FAQs: Minimally Manipulated, Unrelated Cord Blood Products for Clinical Use.
© 2026 Dux Bio. This content is for educational purposes only. Nothing in this article constitutes medical advice or a treatment recommendation. Always consult a licensed healthcare provider for medical decisions.